{"filing":{"accession_number":"0001193125-26-338068","cik":"0001824893","ticker":"SRZNW","company_name":"Surrozen, Inc./DE","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"srzn-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1824893/000119312526338068/srzn-20260806.htm"},"events":[{"id":25643,"run_id":23272,"accession_number":"0001193125-26-338068","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02. The press release announces financial results including revenue ($5.0M collaboration/license revenue), operating expenses (R\u0026D $8.5M, G\u0026A $6.9M), and net income ($50.2M, driven largely by non-cash gains on fair value changes). The filing includes unaudited condensed consolidated statements of operations and comprehensive loss, which are standard components of an earnings disclosure. Material to investors as it provides quarterly financial performance and updates on clinical development milestones.","company_name":"Surrozen, Inc./DE","ticker":"SRZNW","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26528,"accession_number":"0001193125-26-338068","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02. The press release announces financial results including revenue ($5.0M collaboration/license revenue), operating expenses (R\u0026D $8.5M, G\u0026A $6.9M), and net income ($50.2M, driven largely by non-cash gains on fair value changes). The filing includes unaudited condensed consolidated statements of operations and comprehensive loss, which are standard components of an earnings disclosure. Material to investors as it provides quarterly financial performance and updates on clinical development milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:19:29.880282+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26528,"accession_number":"0001193125-26-338068","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02. The press release announces financial results including revenue ($5.0M collaboration/license revenue), operating expenses (R\u0026D $8.5M, G\u0026A $6.9M), and net income ($50.2M, driven largely by non-cash gains on fair value changes). The filing includes unaudited condensed consolidated statements of operations and comprehensive loss, which are standard components of an earnings disclosure. Material to investors as it provides quarterly financial performance and updates on clinical development milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:19:29.880282+00:00","company_name":"Surrozen, Inc./DE","ticker":"SRZNW","filing_date":"2026-08-06"}]}